|
|
Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2010 ... - PR Newswire (press release) |
|
PR Newswire (press release)The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being ... |
|
|
Fish & Richardson Tops Kirkland in Patent Trial Over Dialysis Machines - Corporate Counsel |
|
Corporate CounselKirkland's clients, Baxter Healthcare and DEKA Products, had sued Fresenius Medical Care, claiming that its Liberty Peritoneal Dialysis Cycler infringed two ... |
|
Affymax sees 2nd-quarter profit on payment from Hematide partner Takeda ... - CanadianBusiness.com |
|
CanadianBusiness.comThe company said its regulatory strategy now involves pursuing an application for treatment of anemia in dialysis patients, while continuing to evaluate the ...Affymax and Takeda Announce Preliminary US Registration Strategy for ... |
|
Affymax hopes to ask for Hematide approval in 2011 - BusinessWeek |
|
BusinessWeekThe subgroup of patients were not on dialysis. The drug did meet its effectiveness goals in the study. Affymax said its regulatory strategy now involves ...Affymax and Takeda Announce Preliminary U.S. Registration Strategy for ... |
|
Angiogenesis and chronic kidney disease - 7thSpace Interactive (press release) |
|
7thSpace Interactive (press release)The number of patients requiring renal replacement therapy due to end-stage renal disease (ESRD) is increasing worldwide. The prevalence of Chronic Kidney ... |
|
|
|
|
<< Start < Prev 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 Next > End >>
|
|
Page 1388 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
